You are here

Merck, Samsung Bioepis launch discounted Remicade alternative

Seoul

MERCK & CO and South Korea's Samsung Bioepis Co Ltd said on Monday that they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-

sentifi.com

Market voices on:

Powered by GET.comGetCom